Results 41 to 50 of about 17,568,133 (310)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Cephalalgia, 2020
Objective To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine.
M. Ashina, J. Saper, R. Cady, B. Schaeffler, D. Biondi, J. Hirman, S. Pederson, B. Allan, Jeffrey T. L. Smith   +8 more
semanticscholar   +1 more source

Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen, Wenting Huang, Yitian Liu, Xuan Chen, Buyu Ke, Qian Shen, Hanyu Cai, Jing Sun, Yan Li, Yungang Cao, Beilei Hu, Keyang Chen   +11 more
wiley   +1 more source

Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users

Substance Abuse and Rehabilitation, 2012
Lynn R Webster,1 Robert L Rolleri,2,3 Glenn C Pixton,3 Kenneth W Sommerville31Lifetree Clinical Research, Salt Lake City, UT, USA; 2Salix Pharmaceuticals, Inc., Raleigh, NC, USA; 3Pfizer Inc, Cary, NC, USABackground: Abuse-deterrent formulations attempt ...
Webster LR, Rolleri RL, Pixton GC, Sommerville KW   +3 more
doaj  

Alternatives to Placebo-Controlled Trials [PDF]

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2007
Until recently, the gold standard for assessing the efficacy and effectiveness of new medications has been the placebocontrol randomized clinical trial (RCT). However, there are serious ethical concerns about placing patients on a placebo when effective treatments exist.
openaire   +2 more sources

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Ritalin Side Effects: Placebo Controlled Evaluation

Pediatric Neurology Briefs, 1993
The frequency of side effects of Ritalin was examined in a randomized double-blind placebo-controlled cross-over trial in 206 children aged 5 through 15 years with ADHD at the Marshfield Clinic and Research Foundation, Marshfield, WI.
J Gordon Millichap
doaj   +1 more source

Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang, Lu Lu, Hui Gao, Qi Zhang, Jing Xiao, Josemir W. Sander, Weixi Xiong, Dong Zhou   +7 more
wiley   +1 more source

Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop

Health Technology Assessment, 2021
Background: The use of placebo comparisons for randomised trials assessing the efficacy of surgical interventions is increasingly being considered. However, a placebo control is a complex type of comparison group in the surgical setting and, although ...
David J Beard, Marion K Campbell, Jane M Blazeby, Andrew J Carr, Charles Weijer, Brian H Cuthbertson, Rachelle Buchbinder, Thomas Pinkney, Felicity L Bishop, Jonathan Pugh, Sian Cousins, Ian Harris, L Stefan Lohmander, Natalie Blencowe, Katie Gillies, Pascal Probst, Carol Brennan, Andrew Cook, Dair Farrar-Hockley, Julian Savulescu, Richard Huxtable, Amar Rangan, Irene Tracey, Peter Brocklehurst, Manuela L Ferreira, Jon Nicholl, Barnaby C Reeves, Freddie Hamdy, Samuel CS Rowley, Naomi Lee, Jonathan A Cook   +30 more
doaj   +1 more source